These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19270722)

  • 1. Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo.
    Wei YL; Xu L; Liang Y; Xu XH; Zhao XY
    Acta Pharmacol Sin; 2009 Apr; 30(4):451-7. PubMed ID: 19270722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
    Wei YL; Liang Y; Xu L; Zhao XY
    Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.
    Xu XH; Gan YC; Xu GB; Chen T; Zhou H; Tang JF; Gu Y; Xu F; Xie YY; Zhao XY; Xu RZ
    J Zhejiang Univ Sci B; 2012 Nov; 13(11):867-74. PubMed ID: 23125079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of imatinib and 5-bromotetrandrine on the reversal of multidrug resistance of the K562/A02 cell line.
    Chen BA; Shan XY; Chen J; Xia GH; Xu WL; Schmit M
    Chin J Cancer; 2010 Jun; 29(6):591-5. PubMed ID: 20507731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
    Perkins C; Kim CN; Fang G; Bhalla KN
    Blood; 2000 Feb; 95(3):1014-22. PubMed ID: 10648417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inhibitory effect of 4-chlorobenzoyl berbamine on imatinib-resistant K562 cells in vitro and in vivo].
    Zhang YF; Xu GB; Gan YC; Xu XH; Xu RZ
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Dec; 31(12):1997-2001. PubMed ID: 22200699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.
    Lee YL; Chen CW; Liu FH; Huang YW; Huang HM
    PLoS One; 2013; 8(4):e61939. PubMed ID: 23613979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
    Grimaudo S; Meli M; Di Cristina A; Ferro A; Pipitone MR; Romagnoli R; Simoni D; Dieli F; Tolomeo M
    Anticancer Drugs; 2013 Apr; 24(4):384-93. PubMed ID: 23370613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
    Dai Y; Rahmani M; Corey SJ; Dent P; Grant S
    J Biol Chem; 2004 Aug; 279(33):34227-39. PubMed ID: 15175350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells.
    Ju DS; Kim MJ; Bae JH; Song HS; Chung BS; Lee MK; Kang CD; Lee HS; Kim DW; Kim SH
    Cancer Lett; 2007 Jul; 252(1):75-85. PubMed ID: 17223257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
    Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CaMKII γ, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine.
    Gu Y; Chen T; Meng Z; Gan Y; Xu X; Lou G; Li H; Gan X; Zhou H; Tang J; Xu G; Huang L; Zhang X; Fang Y; Wang K; Zheng S; Huang W; Xu R
    Blood; 2012 Dec; 120(24):4829-39. PubMed ID: 23074277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
    Shi X; Chen X; Li X; Lan X; Zhao C; Liu S; Huang H; Liu N; Liao S; Song W; Zhou P; Wang S; Xu L; Wang X; Dou QP; Liu J
    Clin Cancer Res; 2014 Jan; 20(1):151-63. PubMed ID: 24334603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic effect of 6-Shogaol in Imatinib sensitive and resistant K562 cells.
    Ozkan T; Hekmatshoar Y; Pamuk H; Ozcan M; Yaman G; Yagiz GC; Akdemir C; Sunguroglu A
    Mol Biol Rep; 2021 Feb; 48(2):1625-1631. PubMed ID: 33515349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro.
    Ferrao PT; Frost MJ; Siah SP; Ashman LK
    Blood; 2003 Dec; 102(13):4499-503. PubMed ID: 12881321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation.
    Baran Y; Bielawski J; Gunduz U; Ogretmen B
    J Cancer Res Clin Oncol; 2011 Oct; 137(10):1535-44. PubMed ID: 21833718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
    La Rosée P; Johnson K; O'Dwyer ME; Druker BJ
    Exp Hematol; 2002 Jul; 30(7):729-37. PubMed ID: 12135670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
    Yokota A; Kimura S; Masuda S; Ashihara E; Kuroda J; Sato K; Kamitsuji Y; Kawata E; Deguchi Y; Urasaki Y; Terui Y; Ruthardt M; Ueda T; Hatake K; Inui K; Maekawa T
    Blood; 2007 Jan; 109(1):306-14. PubMed ID: 16954504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
    Wu LX; Wu Y; Chen RJ; Liu Y; Huang LS; Lou LG; Zheng ZH; Chen YZ; Xu JH
    Acta Pharmacol Sin; 2014 Mar; 35(3):401-9. PubMed ID: 24487968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
    Mahon FX; Belloc F; Lagarde V; Chollet C; Moreau-Gaudry F; Reiffers J; Goldman JM; Melo JV
    Blood; 2003 Mar; 101(6):2368-73. PubMed ID: 12609962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.